The computational method leverages Phase Genomics' proprietary proximity-ligation technology based on high-throughput chromosome conformation capture. The method can capture physical genetic linkages inside bacterial cells and identifies DNA sequences that reside within the same organism, specifically in the context of the microbiome.

The technology allows for the discovery and reconstruction of new viral and bacterial genomes, according to the firm. The technology can also measure the host range of newly discovered viruses.

The new platform will aid phage therapy development and infectious disease research. The method and several datasets demonstrating the platform's capabilities were recently published on bioRxiv.

NovoBiome launches to develop microbiome-based therapies
NovoBiome has been launched as a drug discovery company focused on the development of live biotherapeutic products targeting the microbiome-gut-liver...

CRISPR phage offers precision medicine tool to fight bacterial infections
In an attempt to combat bacterial infections, Locus Biosciences is developing bacteriophage therapies that deliver CRISPR-Cas3 machinery directly to specific,...

Galmed, MyBiotics collaborate on microbiome-based treatments
Galmed Pharmaceuticals and MyBiotics Pharma have entered into a research and development collaboration agreement to advance microbiome-based treatments...

Enterome begins trial for microbiome-based immunotherapy
Clinical-stage biopharmaceutical company Enterome has begun its first clinical trial for E02401, a microbiome-based cancer immunotherapy candidate.